Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STOP-V1
NL-OMON60540Phase 3Active, not recruiting
- Sponsor
- Incyte
- Start
- Apr 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in nonsegmental vitiligo and Vitiligo comparing Povorcitinib with Placebo (2 arms). Primary endpoint: F-VASI75 at Week 52. Started Apr 2024; status: active, not recruiting.
02
Drugs
povorcitinib
03
Conditions
nonsegmental vitiligoVitiligo
Beyond the preview
Go deeper on NL-OMON60540.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60540.